Clinical Trials

307 enrolled

Phase 4 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02386800 2026-03-16

CINC424A2X01B Rollover Protocol

279 enrolled

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT03591510 2026-03-13

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

22 enrolled

Leukemia, Myeloid, Acute

NCT07458542 2026-03-09

Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia

44 enrolled

Leukemia, Myeloid, Acute

NCT05316701 2026-03-04

Orca-T

187 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05520567 2026-03-04

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

70 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT06846606 2026-03-03

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

34 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT06052813 2026-02-25

A Study of BN104 in the Treatment of Acute Leukemia

LymphoidOther hematologic neoplasm

66 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05918692 2026-02-23

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

35 enrolled

Leukemia, Myeloid, Acute

NCT05428969 2026-02-20

BEXMAB

181 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT02677922 2026-02-19

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

130 enrolled 38 charts

Leukemia, Leukemia, Myeloid, Acute

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

MyeloidOther hematologic neoplasmPlasma cell

21 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT05197426 2026-02-11

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

19 enrolled 24 charts

Leukemia, Myeloid, Acute

NCT03182244 2026-02-06

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

276 enrolled 41 charts

Leukemia, Myeloid, Acute

NCT05001828 2026-01-21

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

38 enrolled

Leukemia, Myeloid, Acute

NCT06359002 2026-01-20

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

16 enrolled

Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03987958 2026-01-16

REVIVE

100 enrolled

Phase NA Active not recruiting

Leukemia, Myeloid, Acute

NCT06572982 2026-01-14

Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients

20 enrolled

Leukemia, Myeloid, Acute

NCT04657081 2025-12-08

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

101 enrolled

Leukemia, Myeloid, Acute

NCT05413018 2025-12-08

An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

34 enrolled

Leukemia, Myeloid, Acute

NCT05424562 2025-11-28

LIVEN

210 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT03173248 2025-11-10

AGILE

146 enrolled 11 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT04229979 2025-10-01

REGAL

127 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05104775 2025-09-26

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

33 enrolled

Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04023526 2025-08-20

CULMINATE

103 enrolled 19 charts

Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

443 enrolled 14 charts 3 FDA

Leukemia, Myeloid, Acute

NCT04086264 2025-08-14

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

218 enrolled

Phase 4 Active not recruiting

Recurrence, Leukemia, Myeloid, Acute

NCT05144243 2025-08-12

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

44 enrolled

Leukemia, Myeloid, Acute

NCT03190278 2025-08-07

AMELI-01

29 enrolled

Leukemia, Myeloid, Acute

NCT02942290 2025-08-05

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

129 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04891757 2025-07-10

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

144 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04603001 2025-06-27

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

260 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04730258 2025-05-18

TWT-202

72 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT06268574 2025-05-08

RIVER-52

94 enrolled

Leukemia, Myeloid, Acute

NCT04013685 2025-05-02

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

255 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06058741 2025-04-22

VERO

150 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT04150887 2025-04-17

ELEVATE

61 enrolled

Leukemia, Myeloid, Acute

NCT02632708 2025-04-11

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

153 enrolled

Leukemia, Myeloid, Acute

NCT04742101 2025-04-11

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

57 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT05883956 2025-03-20

PREFER-HMA

13 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

NCT05583552 2025-03-14

IMpress

46 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06858618 2025-03-05

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

47 enrolled

Leukemia, Myeloid, Acute

NCT04980885 2025-03-03

A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

68 enrolled

Leukemia, Myeloid, Acute

NCT04623944 2024-12-27

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

61 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03386513 2024-12-16

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

179 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Disorders, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03927261 2024-11-08

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

88 enrolled